ARIAD PHARMACEUTICALS INC (ARIA)
US04033A1007
Insider-Trading Tipster Deserves More Than 18 Months, U.S. Says
The son of a pharmaceutical company director who provided secret information to a participant in a global insider-trading network should be sentenced to more than 18 months in prison, U.S. prosecutors told a judge in New York.
7 Beautiful Biotech Stocks to Buy Here
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
Insider-Trading Witness Gets $10 Million Bail, N.Y. Hotel Room
A Swiss trader who says he raked in $70 million by illegally using secret information from bankers was ordered freed from a New York jail on $10 million bond, after he was the star witness in a trial that shed light on a global insider-trading network.
Global Insider-Trading Probe Lands Conviction of U.S. Leaker
The son of a pharmaceutical-company director was convicted of leaking company secrets to a close friend who prosecutors say was part of a global insider-trading network.
Insider-Trading Witness Says He Bought ‘Burner’ Phones for Boss
An employee of a New York restaurant owner accused of participating in a global insider-trading network told jurors he bought as many as 10 unregistered “burner” phones for his boss.
Global Insider-Trading Ring Linked to Trial of Pharma CEO’s Son
The criminal trial of a New York man may help explain how tens of millions of dollars in illicit profits were allegedly generated by a global insider-trading network that included a Greek pharmaceutical executive, a Goldman Sachs Group Inc. banker, a Monaco poker player, a Swiss trader and a Manhattan restaurant owner.
Pharma Scion in Insider-Trade Case Now Seeks $26 Million Bail
The son of a wealthy Greek pharmaceutical executive proposed an elaborate $26 million bail package to get out of a U.S. jail while he awaits trial over his alleged role in a global insider-trading ring.
3 Monster Biotech Stocks in the Making
Immune Pharma To Unlock Value And Create Two Separate Pure Play Companies; Cytovia, Immune
Immune expects that the focus of Cytovia will be the European market for the drug, which has an addressable market of $175 million, while Pint will focus on the Latin America market with an addressable market of $100 million.